Amylin Pharmaceuticals to Present at JPMorgan Healthcare Conference
January 06 2009 - 4:58PM
PR Newswire (US)
SAN DIEGO, Jan. 6 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals,
Inc. (NASDAQ:AMLN) will be presenting at the JPMorgan Healthcare
Conference in San Francisco on Monday, January 12, 2009 at 10:00
a.m. PT / 1:00 p.m. ET. Daniel M. Bradbury, president and chief
executive officer of Amylin Pharmaceuticals, will be providing a
corporate overview. The live presentation and breakout session will
be webcast, and a recording will be made available following the
event. The webcast and recording will be accessible through
Amylin's corporate Web site, located at http://www.amylin.com/. To
access the live webcast, please log on to Amylin's site
approximately fifteen minutes prior to the presentation to register
and download any necessary audio software. About Amylin
Pharmaceuticals Amylin Pharmaceuticals is a biopharmaceutical
company committed to improving lives through the discovery,
development and commercialization of innovative medicines. Amylin
has developed and gained approval for two first-in-class medicines
for diabetes, SYMLIN(R) (pramlintide acetate) injection and
BYETTA(R) (exenatide) injection. Amylin's research and development
activities leverage the Company's expertise in metabolism to
develop potential therapies to treat diabetes and obesity. Amylin
is headquartered in San Diego, California. Further information
about Amylin Pharmaceuticals is available at
http://www.amylin.com/. DATASOURCE: Amylin Pharmaceuticals, Inc.
CONTACT: Michael York, Senior Director, Investor Relations of
Amylin Pharmaceuticals, Inc., +1-858-552-2200, ext. 8602 Web Site:
http://www.amylin.com/
Copyright
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jul 2023 to Jul 2024